Importantly, CSF1R inhibitors are already an approved class of drug for the treatment of Tenosynovial giant cell tumor, and recent work has established the viability of a CSF1R inhibition-based treatment paradigm for Sandhoff disease, further emphasizing the translatability of this strategy178,179. Here, CSF1R is linked to tenosynovial giant cell tumor.